COMPANY

OncoVerity

Profile checked Oct 10, 2026

Keywords: Leukemia, Myeloid, Acute Myelodysplastic Syndromes ARGX-110

Timeline

Nov 21, 2024 Raise Private equity round — Series A: amount not published, announced Nov 21, 2024. Source: company's own press page. source ↗
Jul 22, 2024 Trial start Phase 2: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy source ↗
Mar 25, 2020 Trial start Phase 1: A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatme source ↗
Dec 23, 2019 Trial start Phase 1: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia source ↗
Jul 29, 2019 Trial start Phase 2: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy source ↗
2016-12 Trial start Phase 1/Phase 2: A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) source ↗
Feb 27, 2013 Trial start Phase 1/Phase 2: A Study of ARGX-110 in Participants With Advanced Malignancies source ↗

2027-01 (ESTIMATED) · Phase 2 · A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy · NCT06384261
May 15, 2027 (ESTIMATED) · Phase 1 · Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia · NCT04150887

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: amount not published. Last 2 years.

Nov 21, 2024 Private equity round — Series A: amount not published, announced Nov 21, 2024. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04150887	Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia	Phase 1	Active, not recruiting	Dec 23, 2019	May 15, 2027 (estimated)
NCT06384261	A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy	Phase 2	Active, not recruiting	Jul 22, 2024	2027-01 (estimated)
NCT04023526	A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy	Phase 2	Active, not recruiting	Jul 29, 2019	Aug 15, 2023 (actual)
NCT01813539	A Study of ARGX-110 in Participants With Advanced Malignancies	Phase 1/Phase 2	Completed	Feb 27, 2013	Jul 10, 2020 (actual)
NCT03030612	A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)	Phase 1/Phase 2	Completed	2016-12	2022-08 (actual)
NCT04241549	A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment	Phase 1	Completed	Mar 25, 2020	Jul 19, 2021 (actual)